Rare diseases
Investigational molecules
Locations
Study on GEN1046 and Pembrolizumab for Patients with Advanced Endometrial Cancer
BelgiumStudy on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer
ItalyStudy of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer
DenmarkStudy Comparing MK-4280A (Favezelimab and Pembrolizumab) with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
BelgiumStudy of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery
AustriaStudy of Pembrolizumab, Paclitaxel, and Bevacizumab for Patients with Platinum-Resistant Recurrent Ovarian Cancer
BelgiumStudy of Pembrolizumab and Lenvatinib for Patients with Advanced Non-Clear Cell Kidney Cancer
FranceStudy of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations
FranceStudy of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer
AustriaStudy of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma
DenmarkStudy of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma
CroatiaStudy of Pembrolizumab and Chemotherapy for Patients with Newly Diagnosed Classical Hodgkin Lymphoma
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
